Genprex, Inc. (NASDAQ:GNPX) Sees Significant Growth in Short Interest

Posted by on Jun 17th, 2025

Genprex, Inc. (NASDAQ:GNPX – Get Free Report) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 2,490,000 shares, a growth of 69.4% from the May 15th total of 1,470,000 shares. Based on an average daily trading volume, of 4,580,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 9.2% of the company’s shares are sold short.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Virtu Financial LLC raised its stake in Genprex, Inc. (NASDAQ:GNPX – Free Report) by 64.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,424 shares of the company’s stock after purchasing an additional 31,400 shares during the quarter. Virtu Financial LLC owned about 0.95% of Genprex worth $68,000 at the end of the most recent quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Trading Up 3.3%

Shares of NASDAQ GNPX traded up $0.01 on Tuesday, reaching $0.32. 106,018 shares of the company traded hands, compared to its average volume of 3,006,941. Genprex has a fifty-two week low of $0.22 and a fifty-two week high of $3.97. The company has a 50 day moving average of $0.28 and a 200 day moving average of $0.49.

Genprex (NASDAQ:GNPX – Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.56. As a group, equities analysts predict that Genprex will post -5.7 earnings per share for the current year.

About Genprex

(Get Free Report)

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.

Featured Articles

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.